Online Database of Chemicals from Around the World

Modafinil
[CAS 68693-11-8]

List of Suppliers
Hefei Scenery Chemical Co., Ltd. China
www.scenery-chem.com
+86 (551) 6512-1814
+86 (551) 6514-1096
sales@scenery-chem.com
Chemical manufacturer
chemBlink Standard supplier since 2007
Changzhou Hangyu Pharmaceutical Technology Co., Ltd. China
www.czyys.com
+86 (519) 8880-2789
+86 13961196887
+86 (519) 8880-2789
sales@czyys.com
zypharm78@hotmail.com
Chemical manufacturer since 1984
chemBlink Standard supplier since 2008
Pratap Organics Pvt. Ltd. India
www.prataporganics.com
+91 (22) 2767-0445
+91 (22) 2763-3555
marketing@prataporganics.com
Chemical manufacturer since 1989
chemBlink Standard supplier since 2010
Hefei TNJ Chemical Industry Co., Ltd. China
www.tnjchem.com
+86 (551) 6541-8684
+86 (551) 6541-8697
sales@tnjchem.com
Chemical manufacturer since 2001
chemBlink Standard supplier since 2010
Chongqing Land Tower Pharmaceutical Co., Ltd. China
www.cqlandtower.com
+86 (23) 6898-0308
+86 (23) 6238-5716
business@cqlandtower.com
Chemical manufacturer since 2010
chemBlink Standard supplier since 2014
Carbosynth China Ltd. China
www.carbosynth.cn
+86 (512) 6260-5585
+86 (512) 6260-5576
sales@carbosynth.com
QQ Chat
Chemical manufacturer since 2006
chemBlink Standard supplier since 2016
Nonsensia Poland
nonsensia.pl
+48 506 848 838
nonsensia@outlook.com
Chemical manufacturer since 2023
chemBlink Standard supplier since 2026
Axon MedChem BV Netherlands
www.axonmedchem.com
+31 (50) 311-8007
+31 (50) 360-0390
order@axonmedchem.com
Chemical manufacturer
Kemprotec Limited UK
www.kemprotec.com
+44 (1642) 591-764
+44 (1845) 550-001
sales@kemprotec.co.uk
Chemical distributor since 1998

Identification
ClassificationAPI >> Nervous system medication >> Other nervous system medication
NameModafinil
Synonyms2-[(Diphenylmethyl)sulfinyl]-acetamide
Molecular StructureModafinil molecular structure (CAS 68693-11-8)
Molecular FormulaC15H15NO2S
Molecular Weight273.35
CAS Registry Number68693-11-8
EC Number640-968-7
SMILESC1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N
Properties
Density1.3±0.1 g/cm3 Calc.*
Boiling point559.1±50.0 °C 760 mmHg (Calc.)*
Flash point292.0±30.1 °C (Calc.)*
SolubilitySoluble DMSO:75 mM,ethanol: 10 mM (Expl.)
Index of refraction1.646 (Calc.)*
*Calculated using Advanced Chemistry Development (ACD/Labs) Software.
Safety Data
Hazard Symbolssymbol symbol   GHS07;GHS08 Warning  Details
Risk StatementsH302-H332-H361d-H373  Details
Safety StatementsP203-P260-P261-P264-P270-P271-P280-P301+P317-P304+P340-P317-P318-P319-P330-P405-P501  Details
Hazard Classification
up    Details
HazardClassCategory CodeHazard Statement
Acute toxicityAcute Tox.4H302
Acute toxicityAcute Tox.4H332
Controlled SubstanceDEA Drug Code Number: 1680   Details
CSA Schedule: IV
Narcotics? No
SDSAvailable
up chemBlink Chemical Story
Modafinil is a wakefulness-promoting prescription drug with an unusual place in the chemistry of nervous-system medicines. Its structure has two phenyl rings joined through a common carbon, a sulfoxide group and a terminal acetamide. Those parts make a different molecular framework from drugs built around a phenethylamine skeleton. Yet a comparison of skeletons is only the start of a pharmacological comparison. It does not tell whether two drugs affect the same transporter, take the same route through the body or have the same clinical uses.

The sulfoxide makes modafinil a convenient example of stereochemistry at sulfur. The two carbon-containing groups attached to sulfur are different. The geometry of the sulfoxide permits two mirror-image arrangements, denoted R and S. Modafinil as supplied in Provigil is a racemate, containing both arrangements, whereas armodafinil denotes the R enantiomer. The distinction is more than a naming convention: the US prescribing information notes that the two enantiomers are eliminated at different rates. The proportion of each in the body after administration therefore need not remain the same as in the starting tablet. A registry entry for the racemate should not be silently replaced by one for an isolated enantiomer.

The United States first approved Provigil in 1998. The US label lists uses for improving wakefulness in adults with excessive sleepiness associated with narcolepsy, obstructive sleep apnea or shift work disorder. In obstructive sleep apnea the treatment addresses sleepiness rather than the physical obstruction. That wording distinguishes a measurable symptom from the cause of the disorder. The same label classifies modafinil as a Schedule IV controlled substance in the United States, a regulatory fact distinct from the chemistry that gives rise to its molecular structure.

Researchers have investigated what happens between administration and the resulting change in wakefulness. In 2009 Volkow and colleagues used positron emission tomography in a small study of healthy men. They measured signals from radiotracers sensitive to dopamine transporters and to changes in extracellular dopamine. The observations supported occupancy of dopamine transporters and increases in extracellular dopamine in several brain regions. These are observations in people under defined conditions, rather than extrapolations from a chemical drawing. At the same time, the scan cannot assign every aspect of the clinical response to a single molecular event. The approved label describes the mechanism by which modafinil promotes wakefulness as unknown.

A useful detail of the imaging study is that it used two different radiotracers. One was used to probe the availability of dopamine transporters. The other bound to dopamine receptors and was used as an indirect probe of changes in extracellular dopamine: endogenous dopamine and the tracer compete for receptor binding. The two readouts are complementary. A change in the first is evidence about access to a transporter, and a change in the second is interpreted in relation to signaling outside cells. Neither observation is the same as counting how many hours a participant felt alert. The methods make the inference more specific by defining what was measured and what still has to be inferred.

Modafinil thus gives three ways to identify what is being discussed: the material can be defined by stereochemistry, a human experiment can probe an effect on a signaling system, and a label can define the purposes for which the product has been evaluated and approved. Each describes a different scale of evidence. The differences between those scales are particularly useful when comparing modafinil with structurally related research compounds that have very different amounts of clinical documentation.

References:
1. DailyMed, Provigil (modafinil), US prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0391f182-1958-9fef-a944-53b229ce99e7
2. Volkow ND et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain. JAMA. 2009;301:1148–1154. https://pubmed.ncbi.nlm.nih.gov/19293415/

Market Analysis Reports
Related Products
MNK1 Inhibitor  Mobecarb  Mobenzoxamine  Mobilat  Mocap  Mociprazine  Moclobemide  Moclobemide N-O...  (S)-(+)-Modafin...  Modafinil-d5  (R)-(-)-Modafin...  (R)-Modafinil C...  (S)-Modafinil C...  Modafinil-d5 Su...  Modaline  Modecainide  Modhephene  Modified methyl...  Modified Starch  rac-Modipafant